Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-07-31
2007-07-31
Blanchard, David J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388100, C530S388850, C424S133100, C424S139100, C424S141100, C424S150100, C435S069600, C435S070210, C435S326000
Reexamination Certificate
active
10323927
ABSTRACT:
The present invention encompasses monoclonal antibodies that bind to lipoteichoic acid (LTA) of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro. The invention also provides antibodies having human sequences (chimeric, humanized and human antibodies). The invention also sets forth the variable regions of three antibodies within the invention and presents the striking homology between them.
REFERENCES:
patent: 4027010 (1977-05-01), Kiselev et al.
patent: 4197290 (1980-04-01), Yoshida
patent: 4425330 (1984-01-01), Norcross et al.
patent: 4460575 (1984-07-01), d'Hinterland
patent: 4482483 (1984-11-01), Curry et al.
patent: 4719290 (1988-01-01), Curry et al.
patent: 4732757 (1988-03-01), Stolle et al.
patent: 4789735 (1988-12-01), Frank et al.
patent: 4830852 (1989-05-01), Marburg et al.
patent: 4902616 (1990-02-01), Fournier et al.
patent: 5034515 (1991-07-01), Proctor et al.
patent: 5055455 (1991-10-01), Pier et al.
patent: 5153312 (1992-10-01), Porro
patent: 5175096 (1992-12-01), Höök et al.
patent: 5354654 (1994-10-01), Ligler et al.
patent: 5440014 (1995-08-01), Höök et al.
patent: 5505945 (1996-04-01), Gristina et al.
patent: 5530102 (1996-06-01), Gristina et al.
patent: 5538733 (1996-07-01), Emery et al.
patent: 5545721 (1996-08-01), Carroll et al.
patent: 5571511 (1996-11-01), Fischer et al.
patent: 5624904 (1997-04-01), Krieger et al.
patent: 5652217 (1997-07-01), Höök et al.
patent: 5770208 (1998-06-01), Fattom et al.
patent: 5776456 (1998-07-01), Anderson et al.
patent: 5840846 (1998-11-01), Höök et al.
patent: 5851535 (1998-12-01), Jolivet-Reynaud
patent: 5955074 (1999-09-01), Fischer et al.
patent: 5955078 (1999-09-01), Burnham et al.
patent: 6111079 (2000-08-01), Wylie et al.
patent: 6610293 (2003-08-01), Fischer et al.
patent: 2002/0082395 (2002-06-01), Fischer
patent: 0 724 016 (1996-07-01), None
patent: WO 89/00999 (1989-02-01), None
patent: WO 90/03398 (1990-04-01), None
patent: WO 93/09811 (1993-05-01), None
patent: WO 93/17044 (1993-09-01), None
patent: WO 93/19373 (1993-09-01), None
patent: WO 94/11026 (1994-05-01), None
patent: WO 96/09321 (1996-03-01), None
patent: WO 96/39518 (1996-12-01), None
patent: WO 97/26010 (1997-07-01), None
patent: WO-98/57994 (1998-12-01), None
Fundamental Immunology, William E. Paul, M.D. ed., 3rd ed., pp. 242, 1993.
Fundamental Immunology, William E Paul, M.D. 3rd ed., pp. 292-295, 1993.
Rudikoff et al. Proc. Natl. Acad. Sci. USA , 79: 1979-1983, 1982.
U.S. Appl. No. 09/097,055 filed Jun. 15, 1998, Fischer et al.
Aasjord and Haaheim, Antibodies to Lipoteichoic Acid fromStaphylococcus aureus , Acta. Path. Microbiol. Immunol. Scand. 93:245-50 (1985).
Ahmad et al., Sequential Release of Antigens from Chloroform-treatedStaphylococcus epidermidis: Application Towards a Possible Vaccine,J. App. Bacteriol. 69:676-85 (1990).
Ahmed et al., Preparation and Efficacy of Staphylococcal Vaccine by Sequential Release of Antigen from Solvent Treated Bacteria,Soc. Appl. Bacter. 67: xv (1989).
Ames, Assay of Inorganic Phosphate, Total Phosphate and Phosphatase,Methods in Enzymology8:115-18 (1966).
Another Sepsis Drug Down—Immunex's TNF Receptor,Biotechnology Newswatch, A. McGraw-Hill Publication, pp. 2-3 (Oct. 4, 1993).
Baird-Parker, The Basis for the Present Classification of Staphylococci and Micrococci, Recent Advances in Staphylococcal Research,Ann. N.Y. Acad. Sci. 236:7-14 (1974).
Baker et al., Multicenter Trial of Intravenous Immunoglobulin (IVIG) to Prevent Late-Onset Infection in Preterm Infants: Preliminary Results,Ped. Res. 25:275A (1989).
Baker et al., Intravenous Immune Globulin for the Prevention of Nosocomial Infection in Low Birth Weight Neonates,New Eng. J. Med. 327:213-19 (1992).
Bonnerjea et al., Protein Purification: The Right Step at the Right Time,Biotechnology4:954-58 (1986).
Borrebaeck,Antibody Engineering, 2nd Ed., Oxford University Press, NY (1995).
Boslego et al., Gonorrhea Vaccines, In Vaccines and Immunotherapy, Chap. 17, Cryz ed., Pergamon Press, pp. 211-223 (1991).
Campbell, Monoclonal Antibodies and Immunosensor Technology,Laboratory Techniques in Biochemistry and Molecular Biology 23, Chapter 1, pp. 1-49 (1991).
Cerozzi et al., Response of CAPD Patients with a High Incidence of Peritonitis to Intraperitoneal Immunoglobulin Therapy,Trans. Am. Soc. Artif. Intern. Organs. 34:635-39 (1988).
Carruthers and Kabat, Mediation of Staphylococcal Adherence to Mucosal Cells by Lipoteichoic Acid,Infect Immun. 40:444-46 (1983).
Chugh et al., Adherence ofStaphyococcus epidermidisto Fibrin-Platelet Clots In Vitro Mediated by Lipoteichoic Acid,Infect Immun. 58:315-19 (1990).
Cieslak et al., Post Immunization Antibodies toS. epidermidisare Broadly Reactive and Opsonic,Ped. Reasearch31:275A (1992).
Clapp et al., Use of Intravenously Administered Immune Globulin to Prevent Nosocomial Sepsis in Low Birth Weight Infants: Report of a Pilot Study,J. Pediatr. 115:973-78 (1989).
Clark et al., Opsonic Requirements ofStaphylococcus epidermidis, J. Med. Microbiol. 22:1-7 (1986).
Clark et al., Opsonic Activity of Intravenous Immunoglobulin Preparations AgainstStaphylococcus epidermidis, J. Clin. Pathol. 39:856-60 (1986).
Current Methods in Hybridoma Formation, Bartal et al. (ed.)Methods of Hybridoma Formation, Humana Press, Clifton, New Jersey (1987).
De Kimpe et al., The Cell Wall Components Peptidoglycan and Lipoteichoic Acid FromS. aureusAct in Synergy to Cause Shock and Multiple Organ Failure,Proc. Nat. Acad. Sci.(USA) 92:10359-63 (1995).
Devereux et al., A Comprehensive Set of Sequence Analysis Programs for the VAX,Nuc. Acids Res. 12:387-95 (1984).
Dick et al., Glycoconjugates of Bacterial Carbohydrate Antigens,Contrib. Microbiol&Immunol. 10:48-114 (1989).
Doyle et al., Soluble Macromolecular Complexes Involving Bacterial Teichoic Acids,J. Bacteriol. 124:341-47 (1975).
Ellis, New Technologies for Making Vaccines, In Vaccines, Chap. 29, W.B. Saunders Co., at 568-75 (Plotkin and Mortimer eds., 1988).
Ellman, Tissue Sulfhydryl Groups,Arch. Biochem. &Biophys. 82:70-77 (1959).
Endl et al., Chemical Composition and Structure of Cell Wall Teichoic Acid of Staphyococci,Arch Microbiol, 135:215-23 (1983).
Espersen et al., Cross-Reactions BetweenStaphyococcus epidermidisand 23 Other Bacterial Species,Acta Path. Microbial. Scand., Sect B. 89:253-60 (1981).
Espersen et al., Solid-Phase Radioimmunoassay for IgG Antibodies toStaphylococcus epidermidis, Arch Intern. Med. 147:689-93 (1987).
Espersen et al.,Staphylococcus aureus, in “Antigen Detection to Diagnose Bacterial Infections” vol. 11, CRC Press Inc., at 127-34 (Kohler, ed., 1986).
Espersen et al., Enzyme-Linked Immunosorbent Assay for Detection ofStaphylococcus epidermidisAntibody in ExperimentalS. epidermidisEndocarditis,J. Clin. Microbiol. 23:339-42 (1986).
Etzioni et al., Effect of Intravenous Gammaglobulin Preparation on the Opsonophagocytic Activity of Preterm Serum Against Coagulase-Negative Staphylococci,Acta. Paediatr. Scand. 79:156-61 (1990).
Exley et al., Monoclonal Antibody to TNF in Severe Septic Shock,Lancet335:1275-1277 (1990).
Fanaroff et al., A Controlled Trial of Intravenous Immune Globulin to Reduce Nosocomial Infections in Very Low Birth Weight Infants,New Eng. J. Med. 330:1107-13 (1992).
Fattom et al., Synthesis and Immunologic Properties in Mice of Vaccines Composed ofStaphylococcus aureusType 5 and Type 8 Capsular Polysaccharides Conjugated toPseudomonas aeruginosaExotoxin A,Infect. &Immun. 58:2367-74 (1990).
Fattom et al., Capsular Polysaccharide Serotyping Scheme forStaphylococcus epidermidis, J. Clin. Micro. 30:3270-73 (1992).
Fischer et al., Diminished Bacterial Defences with Intralipid,Lancet2:819-20 (1980).
Fisher et al., Improved Preparation of Lipoteichoic Acids,Eur. J. Biochem. 133:523-30 (1983).
Fischer et al., Directed Immune Globulin Enhances Survival in an Intralipid Induced Neonatal Model of LethalStaphylococcus epidermidisSepsis,Ped. Res. Abstr. Abstract No. 1670 (Apr. 1991).
Fischer et al., Therapeutic Uses
Fischer Gerald Walter
Lees Andrew
Mond James J.
Schuman Richard F.
Stinson Jeffrey R.
Biosynexus Incorporated
Blanchard David J.
Lahive & Cockfield LLP
LandOfFree
Opsonic monoclonal and chimeric antibodies specific for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Opsonic monoclonal and chimeric antibodies specific for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Opsonic monoclonal and chimeric antibodies specific for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3737624